Pitrakinra

From Wikipedia, the free encyclopedia

[1]

This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (October 2007)

This article does not cite any references or sources. (October 2007) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed.

This article or section needs to be wikified to meet Wikipedia's quality standards. Please help improve this article with relevant internal links. (October 2007)

This page has few or no links to other articles. (Tagged since February 2008). You can improve this article by adding links to related material, within the existing text. For some link suggestions, you can try Can We Link It tool. (You can help!)

Pitrakinra (Aerovant) is a human recombinant protein. It is an IL-4 and IL-13 antagonist in phase IIa studies for Asthma[2]. Its mechanism of action is by interruption of the Th2 lymphocyte immune response that underlies the inflammatory hyperresponsiveness in the airway epithelium of asthmatics.

Asthma results from a dysregulated, hyperresponsive immune response in the airways. Some immune cells in allergic asthmatics respond aggressively to foreign allergens with the release of IL-4 and -13, two key mediators that initiate a cycle of inflammation in the lung. Aerovant is an IL4Ra receptor antagonist that blocks the inflammatory effects of interleukins-4 and -13 (IL-4 and IL-13), thereby promoting a more balanced immune response.